Stay updated on Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page.

Latest updates to the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page
- Check4 days agoChange DetectedThe record now presents details for the nivolumab and ipilimumab renal cell carcinoma study, including its treatment plan, eligibility criteria, outcome measures, study locations, and results-related information.SummaryDifference65%

- Check11 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoChange DetectedAn NIH banner announces a website transition and says NIH content may use “Super Intelligence” instead of “Artificial Intelligence.”SummaryDifference1%

- Check25 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the study details and preventing access to this trial's information. The error page includes a 403 header and footer, indicating restricted access to the record.SummaryDifference20%

Stay in the know with updates to Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page.